Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Prostate Cancer

Free Subscription 26.01.2026 1 BJU Int 2 BMC Cancer 1 BMC Urol 1 Cancer Imaging 1 Clin Cancer Res 1 Clin Imaging 1 Eur Radiol 1 Eur Urol 1 Int J Radiat Oncol Biol Phys 4 Int J Urol 1 J Clin Oncol 1 J Urol 3 N Engl J Med 2 PLoS One 7 Prostate 1 Urol Int 4 Urology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BJU Int

1. KNIEP C, Maurer T, Hartwieg BF, Mandel P, et al
   Diagnostic accuracy and outcomes of lymph node staging in intermediate-risk prostate cancer.
   BJU Int. 2026 Jan 23. doi: 10.1111/bju.70155.
   PubMed         Abstract available
   
   

   
   BMC Cancer

2. LIU W, Kong W, Jiang S, Wei Y, et al
   Integrative transcriptomic profiling reveals subtype-specific therapeutic vulnerabilities and resistance mechanisms in prostate cancer.
   BMC Cancer. 2026;26:97.
   PubMed         Abstract available
   
   
3. ZHONG X, Xiong Y, Yang F, Yang Y, et al
   Prostate health index enhances prostate cancer management in Chinese populations: evidence from the nation's large cohort and transnational multicohort harmonization.
   BMC Cancer. 2026 Jan 20. doi: 10.1186/s12885-026-15577.
   PubMed        
   
   

   
   BMC Urol

4. TOSUN I, Sahin O, Bakkaloglu IG, Sisik NM, et al
   Prognostic significance of neuroendocrine differentiation and PD-L1 expression in treatment-naive prostate cancer.
   BMC Urol. 2026 Jan 17. doi: 10.1186/s12894-026-02053.
   PubMed         Abstract available
   
   

   
   Cancer Imaging

5. LOWRY NC, Breto AL, Wallaengen V, Algohary A, et al
   MRI-based patient selection for active surveillance in prostate cancer using U-Found: a generalized deep learning model.
   Cancer Imaging. 2026 Jan 19. doi: 10.1186/s40644-026-00988.
   PubMed        
   
   

   
   Clin Cancer Res

6. BIDKAR AP, Bidlingmaier S, Wadhwa A, Mayne E, et al
   Synergistic treatment of prostate cancer and multiple myeloma using CD46-targeted radioimmunotherapy-antibody drug conjugates.
   Clin Cancer Res. 2026 Jan 22. doi: 10.1158/1078-0432.CCR-25-4110.
   PubMed         Abstract available
   
   

   
   Clin Imaging

7. COCHRAN RL, Bradley WR, Dhami RS, Milshteyn E, et al
   Comparing prostate diffusion weighted images reconstructed with a commercial deep-learning product to a deep learning phase corrected model at 1.5 T.
   Clin Imaging. 2026;130:110681.
   PubMed         Abstract available
   
   

   
   Eur Radiol

8. MUGLIA VF, Verma S
   ReIMAGINE study insights: Can abbreviated bpMRI transform prostate cancer screening?
   Eur Radiol. 2026 Jan 22. doi: 10.1007/s00330-025-11957.
   PubMed        
   
   

   
   Eur Urol

9. PINI C, Gelardi F, Sollini M, Chiti A, et al
   Targeting Prostatic Acid Phosphatase in Prostate Cancer: Roadmap on How To Venture Above and Beyond Prostate-specific Membrane Antigen with ACP3 Theranostics.
   Eur Urol. 2026 Jan 20:S0302-2838(26)00020-5. doi: 10.1016/j.eururo.2026.
   PubMed        
   
   

   
   Int J Radiat Oncol Biol Phys

10. KEALL PJ, Booth J, Eade T, Hewson EA, et al
    The KIM real-time prostate cancer IGRT technology journey: From clinical trials to your clinic.
    Int J Radiat Oncol Biol Phys. 2026 Jan 18:S0360-3016(26)00083.
    PubMed         Abstract available
    
    

    
    Int J Urol

11. MAKABE S, Hata J, Tsumori T, Hiraguri A, et al
    Abdominal Subcutaneous Fat Thickness Is a Useful Predictor for Lower Urinary Tract Dysfunction After Robot-Assisted Radical Prostatectomy.
    Int J Urol. 2026;33:e70249.
    PubMed         Abstract available
    
    
12. TANAKA H, Kobayashi M, Matsumoto S, Ishikawa Y, et al
    Impact of Approach Routes in MRI-Ultrasound Fusion Prostate Biopsy on Post-Biopsy Complications: A Propensity Score-Matched Analysis.
    Int J Urol. 2026;33:e70275.
    PubMed         Abstract available
    
    
13. SUZUKI Y, Sonobe S, Kawasaki Y, Ikumi S, et al
    Operative Time Prediction by Machine Learning for Robot-Assisted Laparoscopic Radical Prostatectomy.
    Int J Urol. 2026;33:e70292.
    PubMed         Abstract available
    
    
14. CHEN W, Yoshida S, Ikeda R, Yoshimura R, et al
    Oligometastatic Prostate and Bladder Cancer: An Integrative Narrative Review.
    Int J Urol. 2025 Dec 24. doi: 10.1111/iju.70324.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

15. TAPLIN ME, Riaz IB, Rumble RB, Naqvi SAA, et al
    Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1.
    J Clin Oncol. 2026 Jan 20:JCO2502693. doi: 10.1200/JCO-25-02693.
    PubMed         Abstract available
    
    

    
    J Urol

16. SCHLEGEL PN, Vij SC, Filson C, Penzo-Mendez A, et al
    Vasectomy and the Risk of Prostate Cancer.
    J Urol. 2026 Jan 20:101097JU0000000000004937. doi: 10.1097/JU.0000000000004937.
    PubMed        
    
    

    
    N Engl J Med

17. ROOBOL MJ, de Vos II, Auvinen A
    European Study of Prostate Cancer Screening - 23-Year Follow-up. Reply.
    N Engl J Med. 2026;394:410-411.
    PubMed        
    
    
18. THOMPSON IM JR
    European Study of Prostate Cancer Screening - 23-Year Follow-up.
    N Engl J Med. 2026;394:410.
    PubMed        
    
    
19. RAGHAVAN D, Tannock IF
    European Study of Prostate Cancer Screening - 23-Year Follow-up.
    N Engl J Med. 2026;394:410.
    PubMed        
    
    

    
    PLoS One

20. XING S, Xu Z, Zeng S, Yue M, et al
    RIPK2 induces docetaxel resistance in prostate cancer through the NF-kappaB/P-gp signaling pathway.
    PLoS One. 2026;21:e0341445.
    PubMed         Abstract available
    
    
21. 
    Retraction: Mitostatin is down-regulated in human prostate cancer and suppresses the invasive phenotype of prostate cancer cells.
    PLoS One. 2026;21:e0341382.
    PubMed        
    
    

    
    Prostate

22. SUZUKI K, Ueki H, Wakita N, Okamura Y, et al
    Prognostic Impact of Initial Prostate Specific Antigen Half-Life After Abiraterone Acetate in High-Volume Metastatic Hormone-Sensitive Prostate Cancer: Who May Need Triplet Therapy?
    Prostate. 2026 Jan 18. doi: 10.1002/pros.70127.
    PubMed         Abstract available
    
    
23. KANAYAMA M, Daniels VA, Gielzak M, Brame A, et al
    Treatment Response and Outcomes of Prostate Cancer Patients Carrying the Germline MMS22L F722fs Mutation.
    Prostate. 2026 Jan 22. doi: 10.1002/pros.70133.
    PubMed         Abstract available
    
    
24. LI H, Xiong S, Wang M, Liu M, et al
    Development and Validation of a Nomogram for Predicting Pathological Upgrading in Men With Biopsy Gleason 3 + 3 Prostate Cancer Undergoing Radical Prostatectomy: A Population-Based Study.
    Prostate. 2026 Jan 22. doi: 10.1002/pros.70126.
    PubMed         Abstract available
    
    
25. QUARTA L, Polverino F, Petix M, Filzmayer M, et al
    Effect of Marital Status on Years of Life Lost From Metastatic Prostate Cancer According to Race/Ethnicity.
    Prostate. 2026 Jan 22. doi: 10.1002/pros.70130.
    PubMed         Abstract available
    
    
26. OZEN A, Sarikaya Z, Gur C, Ozboru D, et al
    Pelvic Lymph Node Staging With PSMA PET in Prostate Cancer: Surgical Validation With Implications for Radiotherapy Planning.
    Prostate. 2026 Jan 22. doi: 10.1002/pros.70124.
    PubMed         Abstract available
    
    
27. NAKAI Y, Onishi K, Asakawa I, Miyake M, et al
    Effect of Celecoxib Combined With Low-Dose-Rate Brachytherapy on Long-Term Oncological Outcomes and Quality of Life in Prostate Cancer: Post Hoc Analysis of an Open-Label Controlled Randomized Trial.
    Prostate. 2026 Jan 22. doi: 10.1002/pros.70136.
    PubMed         Abstract available
    
    
28. LU J, Lu Y, Kobayashi T, Hachiya T, et al
    Evaluation of Loss of the Y Chromosome in Peripheral Blood as a Biomarker for Prostate Cancer.
    Prostate. 2026 Jan 22. doi: 10.1002/pros.70128.
    PubMed         Abstract available
    
    

    
    Urol Int

29. AYDOGDU C, Urban F, Berg E, Gotz M, et al
    Extended versus Standard Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Cohort Study.
    Urol Int. 2026 Jan 19:1-20. doi: 10.1159/000550580.
    PubMed         Abstract available
    
    

    
    Urology

30. MONTGOMERY J
    Editorial Comment on "Fear of Cancer Recurrence among Uninsured and Underrepresented Men with Prostate Cancer".
    Urology. 2026 Jan 21:S0090-4295(26)00037-3. doi: 10.1016/j.urology.2026.
    PubMed        
    
    
31. SOHONI N, Sohoni NS, Sutherland RA, Sundaresan VM, et al
    Automated Classification of Adverse Events After Hydrogel Perirectal Spacer Insertion for Prostate Cancer Using Large Language Models.
    Urology. 2026 Jan 19:S0090-4295(26)00017-8. doi: 10.1016/j.urology.2026.
    PubMed         Abstract available
    
    
32. PRUITT D, Von P, Gardner T, Paul E, et al
    Assessing Clinical Utility in Randomized Trials of Radical Prostatectomy for Urologic Oncology: An Original Article of Studies Published Between 2020 and 2024.
    Urology. 2026;207:261-266.
    PubMed         Abstract available
    
    
33. WESTERHOUT SF, Rynja SP, van Steenbergen JPZ, Mertens LS, et al
    Antibiotic Prophylaxis Is Not Required Before MRI-Guided Transperineal Prostate Biopsy.
    Urology. 2026;207:166-171.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.